# | Title | Journal | Year | Citations |
---|
1 | Adeno-associated virus vector integration | Current Opinion in Molecular Therapeutics | 2009 | 117 |
2 | Peptoids as potential therapeutics | Current Opinion in Molecular Therapeutics | 2009 | 104 |
3 | Shotgun proteomics: tools for the analysis of complex biological systems | Current Opinion in Molecular Therapeutics | 2002 | 96 |
4 | MicroRNAs: biogenesis, function and applications | Current Opinion in Molecular Therapeutics | 2009 | 94 |
5 | AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia | Current Opinion in Molecular Therapeutics | 2010 | 90 |
6 | BiTE: Teaching antibodies to engage T-cells for cancer therapy | Current Opinion in Molecular Therapeutics | 2009 | 88 |
7 | Personalized medicine | Current Opinion in Molecular Therapeutics | 2002 | 85 |
8 | Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview | Current Opinion in Molecular Therapeutics | 2009 | 79 |
9 | Novel functions for small RNA molecules | Current Opinion in Molecular Therapeutics | 2009 | 72 |
10 | CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease | Current Opinion in Molecular Therapeutics | 2010 | 72 |
11 | BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers | Current Opinion in Molecular Therapeutics | 2010 | 71 |
12 | Immunogenicity of therapeutic monoclonal antibodies | Current Opinion in Molecular Therapeutics | 2003 | 68 |
13 | Off-targeting and other non-specific effects of RNAi experiments in mammalian cells | Current Opinion in Molecular Therapeutics | 2007 | 67 |
14 | Virus combinations and chemotherapy for the treatment of human cancers | Current Opinion in Molecular Therapeutics | 2008 | 67 |
15 | NMR-based metabolomics: translational application and treatment of cancer | Current Opinion in Molecular Therapeutics | 2007 | 66 |
16 | Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials | Current Opinion in Molecular Therapeutics | 2010 | 66 |
17 | Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs | Current Opinion in Molecular Therapeutics | 2010 | 65 |
18 | High-capacity 'gutless' adenoviral vectors | Current Opinion in Molecular Therapeutics | 2001 | 65 |
19 | Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration | Current Opinion in Molecular Therapeutics | 2005 | 65 |
20 | Subcutaneous administration of biotherapeutics: current experience in animal models | Current Opinion in Molecular Therapeutics | 2010 | 65 |
21 | Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans | Current Opinion in Molecular Therapeutics | 2004 | 64 |
22 | Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders | Current Opinion in Molecular Therapeutics | 2009 | 64 |
23 | mRNA-based gene transfer as a tool for gene and cell therapy | Current Opinion in Molecular Therapeutics | 2007 | 61 |
24 | Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss | Current Opinion in Molecular Therapeutics | 2010 | 60 |
25 | Overview of phase I studies of intravenous administration of PV701, an oncolytic virus | Current Opinion in Molecular Therapeutics | 2003 | 59 |
26 | The therapeutic potential of antisense-mediated exon skipping | Current Opinion in Molecular Therapeutics | 2008 | 59 |
27 | RNAi therapeutics: an update on delivery | Current Opinion in Molecular Therapeutics | 2008 | 59 |
28 | Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain | Current Opinion in Molecular Therapeutics | 2010 | 58 |
29 | The use of neural stem cells in cancer gene therapy: predicting the path to the clinic | Current Opinion in Molecular Therapeutics | 2010 | 57 |
30 | Enhancing vaccines with immune stimulatory CpG DNA | Current Opinion in Molecular Therapeutics | 2001 | 56 |
31 | Metabonomics: systems biology in pharmaceutical research and development | Current Opinion in Molecular Therapeutics | 2004 | 56 |
32 | Clinical trials in neurological disorders using AAV vectors: promises and challenges | Current Opinion in Molecular Therapeutics | 2004 | 54 |
33 | Shotgun proteomics: integrating technologies to answer biological questions | Current Opinion in Molecular Therapeutics | 2003 | 53 |
34 | Immunoliposomes for cancer therapy | Current Opinion in Molecular Therapeutics | 2006 | 50 |
35 | Newcastle disease virus as a vaccine vector for humans | Current Opinion in Molecular Therapeutics | 2008 | 50 |
36 | NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells | Current Opinion in Molecular Therapeutics | 2008 | 50 |
37 | Malaria vaccines: are we getting closer? | Current Opinion in Molecular Therapeutics | 2007 | 49 |
38 | Evading the immune response upon in vivo gene therapy with viral vectors | Current Opinion in Molecular Therapeutics | 2009 | 47 |
39 | Striking out at disseminated metastases: the systemic delivery of oncolytic viruses | Current Opinion in Molecular Therapeutics | 2006 | 47 |
40 | Drug evaluation: the C5a receptor antagonist PMX-53 | Current Opinion in Molecular Therapeutics | 2006 | 47 |
41 | Antivector and antitransgene host responses in gene therapy | Current Opinion in Molecular Therapeutics | 2000 | 46 |
42 | The host response to cancer virotherapy | Current Opinion in Molecular Therapeutics | 2008 | 46 |
43 | Cancer therapy with bispecific antibodies: Clinical experience | Current Opinion in Molecular Therapeutics | 2010 | 45 |
44 | Polyethylenimines for in vivo gene delivery | Current Opinion in Molecular Therapeutics | 2001 | 45 |
45 | Improving DNA vaccine potency via modification of professional antigen presenting cells | Current Opinion in Molecular Therapeutics | 2003 | 45 |
46 | Prime-boost immunization strategies for infectious diseases | Current Opinion in Molecular Therapeutics | 2002 | 44 |
47 | Proteomics approaches towards antigen discovery and vaccine development | Current Opinion in Molecular Therapeutics | 2002 | 44 |
48 | Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions | Current Opinion in Molecular Therapeutics | 2009 | 44 |
49 | Cytokine- and chemokine-based gene therapy for cancer | Current Opinion in Molecular Therapeutics | 2003 | 43 |
50 | Small interfering RNA for experimental cancer therapy | Current Opinion in Molecular Therapeutics | 2005 | 43 |